Alert: New Earnings Report (11/2/23)-Ionis Pharmaceuticals Inc (NASDAQ: IONS).


For its third fiscal quarter (ending September 30), Ionis Pharmaceuticals Inc (NASDAQ: IONS) has reported E.P.S. of $-1.03 compared to $-0.33 a year ago. This performance was $-0.14 short of the consensus estimate of $-0.89. E.P.S. were $-2.87 for the latest four quarters through September 30 versus $0.06 for the same period a year ago — a decline of -4883%.


Recent Price Action

On 11/2/23, Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock suffered a large decline of -3.4%, closing at $43.73. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -1.4% during the last week.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to exceed the cost of capital, IONS is expected to be a modest Value Builder.

Ionis Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Ionis Pharmaceuticals has a very low Appreciation Score of 2 but a good Power Rating of 83, triggering the Negative Value Trend Rating.

Rating Review

In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.